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Chronic hepatitis C (CHC) patients frequently suﬀer from thyroid disorders during interferon therapy. However, the mechanism
remains unclear. In this study, we investigated the association between serum B-cell-activating factor belonging to the TNF family
(BAFF) levels and the presence of antithyroid peroxidase antibody (anti-TPO) in CHC patients treated with pegylated interferon
alpha and ribavirin combination therapy. Six months after the therapy, anti-TPO antibody was detected in 10 (males, 1; females,
9) of 50 patients. The mean age of these patients was higher than that of the anti-TPO-negative patients (61yr versus 55yr). Before
treatment,theserumBAFFlevelsoftheanti-TPO-positivepatientswerehigherthanthoseoftheanti-TPO-negativepatients.After
starting therapy, the serum BAFF levels of both the anti-TPO-positive and -negative patient groups were elevated. Our ﬁndings
suggest that the serum BAFF concentration before therapy can predict the risk of thyroid autoimmunity in elderly female patients
with CHC.
1.Introduction
Interferon alpha (IFNα) is a type I interferon that has been
widely used as a therapeutic agent, mostly for infectious
diseases,includingchronichepatitisCvirus(HCV)infection
[1]. IFNα therapy is associated with many side eﬀects such
as ﬂu-like symptoms, hematologic disorders, and neuropsy-
chiatric disorders [2]. One of the commonest side eﬀects of
IFNα therapy is autoimmune thyroid disorders manifesting
as Hashimoto’s thyroiditis, Graves disease, or the production
of thyroid autoantibodies without any thyroid dysfunction
[3–5]. However, the detailed mechanism of these eﬀects is
unknown.
B-cell-activating factor belonging to the TNF family
(BAFF), which is also known as BLyS, TALL-1, zTNF4,
or THANK, is part of the TNF family and is known to
play an important role in the diﬀerentiation of B cells
and the maintenance of mature B-cell shape [6–10]. BAFF
is expressed on the surfaces of monocytes, dendritic cells,
neutrophils, activated T cells, malignant B cells, and epithe-
lial cells [6–10]. BAFF plays an important role in humoral
immunity.
The N-terminal sequence of human BAFF contains a
furin cleavage site that is responsible for the release of
soluble BAFF [8]. After the development of ELISA using
monoclonal antibody, high concentrations of BAFF were
clinically measured in patients with autoimmune diseases
suchasrheumatoidarthritis,autoimmunediabetes,Sj¨ ogren’s
syndrome, and multiple sclerosis [11–15]. It was further
found that BAFF aﬀects the regulation of the interaction
between antigen-presenting cells and T cells, resulting in the
emergence of several autoantibodies [16].2 Clinical and Developmental Immunology
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Figure 1: Clinical features (age, sex) of CHC patients. (a) patients who developed anti-TPO antibodies (n = 10) at six months after the
start of peg-interferon and ribavirin therapy. (b) Patients who not developed anti-TPO antibodies (n = 40) at six months after the start of
peg-interferon and ribavirin therapy. ∗P<0.05 was statistically signiﬁcant.
So, in the present study, to address the onset mechanism
of IFN-induced thyroid autoimmunity, we investigated anti-
TPO antibodies and serum BAFF levels in chronic hepatitis
C (CHC) patients treated with IFNα.
2.MaterialsandMethods
2.1. Patients. Fifty CHC patients (males, 24; females, 26)
who received pegylated interferon alpha (PEG-IFNα 2b) and
ribavirin therapy were enrolled in this study. Their mean
age was 57.0 ± 7.1 years old. All patients were diagnosed
with chronic hepatitis based on liver pathological ﬁndings
and were positive for serum HCV RNA before therapy.
After obtaining written informed consent, venous blood was
collected by venipuncture and was permitted to clot. Serum
samples were collected and stored at −70◦C.
Serum anti-TPO antibody, TSH, and free T4 levels were
examined prior to therapy and six months after the start
of therapy using commercially available ECLIA kits (MBL,
Nagoya, Japan and Eiken, Tokyo, Japan). The standard values
of anti-TPO, TSH, and free T4 are less than 16IU/mL,
0.5–5.0μIU/mL, and 0.9–1.7ng/dL, respectively. Prior to
therapy, all patients were conﬁrmed to be negative for anti-
TPO and to be within normal limits for TSH and free
T4.
2.2. Serum BAFF Concentration. The serum BAFF concen-
tration was examined by a commercially available sand-
wich ELISA, the Quantikine Human BAFF/BLyS/TNFSF13B
Immunoassay (R&D Systems, MI, USA), using monoclonal
antibody speciﬁc to BAFF [11]. All of the subjects’ serum
samples were assayed on the same day. The standard serum
BAFF value was set from sera of 72 healthy control subjects
(males, 35; females, 37. mean age, 56.3 ±6.2y.o.).
2.3. Statistical Analysis. Data are expressed as the mean ±
standard deviation (SD), and all analyses were performed
using the nonparametric Mann-Whitney test and chi-square
test. We considered P values of <0.05 to be signiﬁcant.
3. Results
3.1. Anti-TPO Antibody, TSH, and Free T4 Levels. Before
therapy, all study patients were negative for anti-TPO
antibody. Six months after the start of treatment, anti-TPO
antibodies were newly detected in 10 (20%) of 50 patients.
Hereafter, the 10 patients in whom anti-TPO antibody was
detectedsixmonthsafterthestartofIFNtherapyarereferred
to as group A and the other 40 patients are referred to as
group B. As shown in Figure 1, the mean age of the group
A patients (61.2 ± 3.8y.o.) was signiﬁcantly higher than that
of group B (55.6 ± 7.9y.o.) (P = 0.03). The female-to-male
ratio of group A was 90% (males, 1; females, 9), and that of
group B was 42.5% (males, 23; females, 17). The diﬀerence
betweenthetwogroupswassigniﬁcant(P = 0.001).Ingroup
A, the mean TSH level before therapy was 1.7 ± 0.6μIU/mL,
and that at six months after the start of IFN therapy was
2.1 ±1.4μIU/mL. The mean free T4 level before therapy was
1.1 ± 0.1ng/mL, and that at six months after the start of
IFN therapy was 1.3 ± 0.3ng/mL. There was no signiﬁcant
diﬀerencebetweenthetwogroups. Inaddition, thesustained
vir ologicalr esponserateingr oupAwas60%(6/10),andthat
in group B was 50% (20/40), which were not signiﬁcantly
diﬀerent.Clinical and Developmental Immunology 3
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Figure 2: Serum BAFF concentrations of (a, b) (before treatment, at 6 months after the start of therapy) and healthy control subjects.
∗P<0.05 was statistically signiﬁcant.
3.2. Serum BAFF Levels. As shown in Figure 2, the mean
serum BAFF level prior to IFN therapy in group A (1497.4 ±
319.4pg/mL) was signiﬁcantly higher than that in group
B (1139.5 ± 359.1pg/mL) and healthy control subjects
(1105.0 ± 215.2pg/mL)(P<0.05). The mean serum BAFF
levels of both A and B groups were higher at six months
after the start of IFN therapy than before therapy; however,
they were not signiﬁcantly diﬀerent (group A: 2177.8 ±
753.3pg/mL, group B: 2302.3 ±660.6pg/mL).
4. Discussion
Recentwell-controlledstudiesdemonstratedthatbothhypo-
thyroidism and thyroid autoimmunity were signiﬁcantly
more common in patients with CHC than in the control
population [17, 18]. Moreover, in CHC patients treated
with IFNα, these thyroid disorders were well recognized as
serious side eﬀects. Previously, it was found that among
CHC patients that received IFN therapy, elderly women were
shown to have a 4.4 times higher risk of developing thy-
roid dysfunction than men [5]. Our ﬁndings were concord-
ant with these previous ﬁndings. However, the detailed
mechanism of IFN-induced thyroid autoimmunity remains
unknown [19, 20].
Recently, BAFF was identiﬁed to be a 285-amino-acid
protein that belongs to the TNF ligand superfamily [6–10].
After a serum BAFF assay was developed using a monoclonal
antibody, clinical studies of several autoimmune diseases
were conducted [11–15]. In particular, BAFF was found to
be strongly associated with the emergence of several autoan-
tibodies [16]. So, in the present study, we investigated the
relationship between IFN-induced thyroid autoimmunity
and serum BAFF.
First, the serum BAFF baseline levels before IFN therapy
were signiﬁcantly higher in group A than in group B. No dif-
ference was observed between group B and healthy control
subjects. This result indicates that a high serum BAFF level
before IFN therapy is a risk factor aﬀecting the development
of thyroid autoimmunity during IFN therapy. IFNα can
cause a signiﬁcant increase in anti-TPO levels in individuals
who are positive for anti-TPO before IFN therapy [5]. Even
in individuals in whom autoantibody tests were negative
before IFN therapy, it was suggested that autoimmunity
includingthyroiddisorderswasampliﬁedbyIFNαtherapyin
patients showing high serum concentrations of BAFF before
therapy.
Second, the mean serum BAFF levels detected at six
months after the start of IFN therapy were signiﬁcantly
higher than those observed before therapy in both groups;
that is, we found that serum BAFF levels were increased by
IFN therapy.
Interestingly, there was a case undergoing type I IFN
therapy developed RA, and this was also associated with
increased levels of BAFF [21]. One potential consequence of
high BAFF levels is the emergence of autoimmunity during
IFNα therapy.
Finally, based on the hypothesis that BAFF might pro-
mote autoimmune diseases [22], clinical trials using BAFF
inhibitors have been performed in RA and SLE patients [23].
These results could lead to the development of new strategies
for treating IFN-induced thyroid autoimmunity.
5. Conclusion
Our ﬁndings suggest that the high values of serum BAFF
concentration before IFN therapy can predict the risk of
thyroid autoimmunity in elderly female patients with CHC.4 Clinical and Developmental Immunology
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